GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

Shares of RAPT Therapeutics surged sharply on Tuesday after the biopharmaceutical company said it had agreed to be acquired ...

South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...

Shares in RAPT Therapeutics Inc (NASDAQ:RAPT) soared 63.6% on Tuesday after pharmaceutical major GSK plc (LSE:GSK) said it ...

GSK has agreed to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel ...

GSK to acquire California-based biopharma company, RAPT Therapeutics for $2.2 billion: London, UK Tuesday, January 20, 2026, 16:45 Hrs [IST] GSK plc announced that it has entered ...

Viking has identified Neil Aubuchon as the person to oversee its commercial preparations. Aubuchon has joined the biotech as ...

GSK touted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults ...